270Surgical

Company Overview

Snapshot

Founded in June 2016 by Avi Levy, 270Surgical operates with 11–50 employees. The company has secured funding across two rounds from 5 investors. In November 2019, 270Surgical announced FDA clearance for its extended field-of-view laparoscopic system.

Business overview

270Surgical is dedicated to enhancing laparoscopic surgery through its specialty system, which provides a 270-degree field of view, significantly improving visualization compared to standard systems. This technology also addresses common issues like lens fogging and enhances visibility through smoke. The company's SurroundScope system is fully compatible with existing operating room equipment and is initially targeting the bariatric, foregut, and colorectal laparoscopy markets within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Diagnostics Devices.

Strategic signal

In January 2020, 270Surgical received CE Mark clearance for its SurroundScope System, enabling its commercialization in Europe. This regulatory approval is a significant validation of the company's technology and opens up a major new market for its extended field-of-view laparoscopic system, signaling strong potential for international expansion and increased adoption among healthcare providers.

Company Intelligence Q&A

What is 270Surgical's core product?

270Surgical's core product is the SurroundScope System, a specialty laparoscopic system designed to provide a 270-degree field of view, improve visualization by eliminating lens fogging, and enhance clarity through smoke during surgical procedures.

When was 270Surgical founded?

270Surgical was founded in June 2016.

Has 270Surgical received any regulatory clearances for its products?

Yes, 270Surgical announced FDA clearance for its extended field-of-view laparoscopic system in November 2019 and CE Mark clearance for its SurroundScope System in January 2020.

Which markets does 270Surgical initially target?

270Surgical's specialty laparoscopic system will first target the bariatric, foregut, and colorectal laparoscopy markets.